NCT05593081Recruiting
Multicenter Study of Fulminant Type 1 Diabetes in China
Source: ClinicalTrials.gov · Last updated 25 Oct 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study took FT1D（fulminant type 1 diabetes） as the research object, collected the cases of FT1D patients, and described the clinical characteristics of this type of disease. The HLA susceptibility genes of FT1D were identified by PCR and other techniques, taking age-sex-matched healthy subjects as controls and HLA genes as the research entry point.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 240 (estimated)
- First submitted
- 18 Oct 2022
- Start date
- 20 May 2022
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Diseases
- Type 1 diabetes
- NCT number
- NCT05593081
What you commit to
- Study type: Observational
- Planned participants: 240
- From 20 May 2022 to the primary completion date, 31 Dec 2027
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Case reports of previously diagnosed with diabetes were excluded.
Other illness
- The exclusion criteria were as follows: (1) with heart, brain, liver, kidney or other chronic diseases; (2) with other types of autoimmune diseases; (3) with malignant tumors; (4) with a family history of diabetes.
Other
- Healthy Volunteers
Who the study is looking for
- 1\) diabetic ketosis or ketoacidosis occurred soon after the onset of hyperglycemic symptoms; 2) patient presented with plasma glucose ≥16.0 mmol/L and HbA1c \<8.7% at the first visit; and 3) patient had urinary C-peptide excretion \<10 µg/day,fasting serum C-peptide level \<0.10 nmol/L, or postprandial serum C-peptide \<0.17 nmol/L at onset
- Normal control: The inclusion criteria are as follows: (1) Oral glucose tolerance test (OGTT): fasting blood glucose (FPG) \<5.6 mmol/L and postprandial 2 h blood glucose (PPG) \<7.8 mmol/L. The participants voluntarily signed the informed consent and extracted 3ml of peripheral blood for DNA extraction.
Criteria the registry did not label
- patients with fulminant 1 diabetes
Sex: All · Accepts healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Changsha Central Hospital Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
| The Second Xiangya Hospital of Central South University Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
| The First Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
| Hainan Provincial People's Hospital Coordinator of this site? Confirm its status | Haikou | China | Recruiting |
| Yunnan Provincial People's Hospital Coordinator of this site? Confirm its status | Kunming | China | Recruiting |
| The First Affiliated Hospital of NanChang University Coordinator of this site? Confirm its status | Nanchang | China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University Coordinator of this site? Confirm its status | Nanning | China | Recruiting |
| Quanzhou First People's Hospital Coordinator of this site? Confirm its status | Quanzhou | China | Recruiting |
| Yancheng Third People's Hospital Coordinator of this site? Confirm its status | Yancheng | China | Recruiting |
| Guizhou Provincial People's Hospital Coordinator of this site? Confirm its status | Zunyi | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.